Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | GAA | P10253 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | THRB | P10828 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | GFER | P55789 | 1/20 | 0.76 |
| ▸ | PLEC | Q15149 | 1/20 | 0.76 |
| ▸ | PRKCI | P41743 | 1/20 | 0.67 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1731245 | 0.86 | GAA (1.00) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL3063269 | 0.86 | KDM4E (0.57) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL1543144 | 0.83 | GAA (0.71) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL3440911 | 0.82 | PRKCI (0.61) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL14800323 | 0.81 | PTGER4 (0.73) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL21310896 | 0.81 | PRKCI (0.64) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL1643562 | 0.81 | MAPT (0.50) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL2245773 | 0.80 | PRKCI (1.00) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL3070660 | 0.80 | HTT (0.58) | KDM4EALDH1A1GAAMAPTTHRB | |
| SCHEMBL7224988 | 0.80 | PRKCI (0.58) | KDM4EALDH1A1GAAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7902237-B2 | nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels | EXELIXIS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902237-B2 | nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels | EXELIXIS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902237-B2 | nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels | EXELIXIS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1776112-A2 | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2006020680-A2 | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1465882-A4 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1465882-A2 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003060078-A9 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | disclosed |
| WO-2003060078-A2 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | KDM4E 3294/4885ALDH1A1 2884/4885GAA 3489/4885 |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | CNR1, CNR2, TACR2 | KDM4E 4779/4885ALDH1A1 1537/4885GAA 545/4885 |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | KDM4E 3294/4885ALDH1A1 2884/4885GAA 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.